OBJECTIVE: To investigate neurochemical changes in the caudate nucleus of pediatric obsessive-compulsive disorder (OCD) patients before and after cognitive-behavioral therapy (CBT), and to examine corresponding changes in symptom severity. METHOD: Single-voxel proton magnetic resonance spectroscopic (1H-MRS) examination of the left caudate was conducted in 21 treatment-naïve children, aged 6 to 16 years, before and after 12 weeks of CBT. Subjects were measured at baseline and posttreatment by the Yale-Brown Obsessive Compulsive Scale for Children, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale. RESULTS: No significant changes in caudate neurochemistry were observed in OCD patients before and after CBT despite unambiguous improvement in OCD symptoms, depression, and anxiety. CONCLUSIONS: Findings suggest that reduction in caudate Glx may be specific to SSRI treatment and not due to a more generalized treatment response or spontaneous improvement of symptoms. Differential sets of pathophysiologic and treatment response markers may moderate/mediate the effects of particular treatments on outcome.
OBJECTIVE: To investigate neurochemical changes in the caudate nucleus of pediatric obsessive-compulsive disorder (OCD) patients before and after cognitive-behavioral therapy (CBT), and to examine corresponding changes in symptom severity. METHOD: Single-voxel proton magnetic resonance spectroscopic (1H-MRS) examination of the left caudate was conducted in 21 treatment-naïve children, aged 6 to 16 years, before and after 12 weeks of CBT. Subjects were measured at baseline and posttreatment by the Yale-Brown Obsessive Compulsive Scale for Children, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale. RESULTS: No significant changes in caudate neurochemistry were observed in OCDpatients before and after CBT despite unambiguous improvement in OCD symptoms, depression, and anxiety. CONCLUSIONS: Findings suggest that reduction in caudate Glx may be specific to SSRI treatment and not due to a more generalized treatment response or spontaneous improvement of symptoms. Differential sets of pathophysiologic and treatment response markers may moderate/mediate the effects of particular treatments on outcome.
Authors: Paul Daniel Arnold; Frank P Macmaster; Gregory L Hanna; Margaret A Richter; Tricia Sicard; Eliza Burroughs; Yousha Mirza; Phillip C Easter; Michelle Rose; James L Kennedy; David R Rosenberg Journal: Brain Imaging Behav Date: 2009-03-01 Impact factor: 3.978
Authors: Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi Journal: Neuropsychopharmacology Date: 2017-04-04 Impact factor: 7.853
Authors: Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-10-01 Impact factor: 5.067
Authors: Joseph O'Neill; Eda Gorbis; Jamie D Feusner; Jenny C Yip; Susanna Chang; Karron M Maidment; Jennifer G Levitt; Noriko Salamon; John M Ringman; Sanjaya Saxena Journal: J Psychiatr Res Date: 2013-01-04 Impact factor: 4.791
Authors: Ke Wu; Gregory L Hanna; Philip Easter; James L Kennedy; David R Rosenberg; Paul D Arnold Journal: Psychiatry Res Date: 2012-11-13 Impact factor: 3.222